Anavex Life Sciences Corp (AVXL)

[falconer66a]

Like the trends.

Well, I purchased a few hundred AVXLs this morning, at $18.52. It’s my first purchase in several years; had a few discretionary dollars to put to work (well, bet on increasing value of AVXL). At the end of the trading day, very satisfied.

I then listened to the segments of the online conference call that weren’t silent. Everything I heard confirmed my expectations; all positive. When the transcript gets posted, I’ll scrutinize everything and re-evaluate. But with Rett results out in the second half of the year, Christmas may be rather joyous. Those data points will substantiate in humans the blarcamesine mechanism of action (MOA), activating the sigma-1 receptor protein, with all of the consequent good things in neurons. The murine (lab rodent) data are revolutionary, but discounted because mice aren’t men (or girls with Rett syndrome).

When the Rett and Alzheimer’s trials data are released, late this year and into next, postings on the Anavex Ihub board (this one) will be different. Gonna be hard to tell how bad Missling is, and how blarcamesine is a failure.

From the start of my interest (and equity investment) in Anavex Life Sciences Corp a number of years ago I’ve always looked to 2023 to be the year of the company’s operating success. It will then be selling blarcamesine across much of the globe, for a diversity of indications. Right now, my composite AVXL cost basis price is $2.33. In a few years, should I be liquidating any of my position (have no intention of doing so), I’d have some substantial capital gains taxes. Instead, I intend to hold my position, reap eventual dividends, but pass the position on to my estate beneficiaries, my wife and children.

Everything trending as anticipated; slowly but deliberately.